Efficacy of Decreased Dosage of Amoxicillin in an Eradication Remedy for Helicobacter pylori An infection in Sufferers on Hemodialysis: A Randomized Managed Trial – Summary – Digestion 2018, Vol. 97, No. 2

Systematic DNA Study for Fabry Disease in the End Stage Renal Disease Patients from a Southern Italy Area - FullText - Kidney and Blood Pressure Research 2018, Vol. 43, No. 4
March 11, 2021 0 Comments


Sahara S.a· Sugimoto M.a,d· Ichikawa H.a· Kagami T.a· Sakao Y.f· Ohashi N.a· Horio Y.e· Sugimoto Okay.a· Kato A.b· Furuta T.c· Yasuda H.a

Creator affiliations

aFirst Division of Medication, Hamamatsu, Japan
bBlood Purification Unit, Hamamatsu, Japan
cHeart for Medical Analysis, Hamamatsu College Faculty of Medication, Hamamatsu, Japan
dDivision of Digestive Endoscopy, Shiga College of Medical Science Hospital, Otsu, Japan
eDivision of Gastroenterology, Municipal Kosai Hospital, Kosai, Japan
fHamana Clinic, Hamamatsu, Japan

Digestion 2018;97:163–169

Log in to MyKarger to verify if you have already got entry to this title.

Purchase

  • FullText & PDF
  • Limitless re-access through MyKarger
  • Unrestricted printing, no saving restrictions for private use

Extra Data” href=”https://www.karger.com/Article/Summary/#” class=”moreInfo” data-toggle=”popover” data-placement=”proper” data-content=”Construct your private Karger library: All transactional particulars are saved to MyKarger, together with article hyperlinks for simple entry any time from anyplace.” title=””>learn extra


CHF 38.00 *
EUR 35.00 *
USD 39.00 *


Choose

KAB

Purchase a Karger Article Bundle (KAB) and revenue from a low cost!

If you need to redeem your KAB credit score, please log in.


Save over 20% in comparison with the person article value.


Be taught extra

Lease/Cloud

  • Lease for 48h to view
  • Purchase Cloud Entry for limitless viewing through totally different units
  • Synchronizing within the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Choose

Subscribe

  • Entry to all articles of the subscribed 12 months(s) assured for five years
  • Limitless re-access through Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for private use

You obtain your entry authorization inside just a few days; please copy this text reference into your MySelection.” title=””>learn extra


Subcription charges


Choose

* The ultimate costs could differ from the costs proven as a consequence of specifics of VAT guidelines.


Article / Publication Particulars

First-Web page Preview

Abstract of Original Paper

Obtained: September 14, 2017
Accepted: November 04, 2017
Revealed on-line: January 08, 2018
Subject launch date: February 2018

Variety of Print Pages: 7
Variety of Figures: 4
Variety of Tables: 3

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (On-line)

For added info: https://www.karger.com/DIG

Summary

Background: An optimum Helicobacter pylori-eradication routine for hemodialysis sufferers is but to be established due to totally different pharmacokinetics of amoxicillin concerned between hemodialysis sufferers and wholesome topics. We investigated to ascertain acceptable doses of amoxicillin for H. pylori an infection eradication in hemodialysis sufferers. Strategies: Of 409 hemodialysis sufferers screened for H. pylori an infection, 37 H. pylori-positive sufferers have been randomized to totally different 1-week eradication regimens: esomeprazole 20 mg twice a day (b.i.d.) and clarithromycin 200 mg b.i.d., plus amoxicillin at both 750 mg b.i.d. (group A; typical) or 250 mg b.i.d. (group B; experimental). Sixty-three sufferers with regular renal operate obtained the standard routine (group C). Profitable eradication was confirmed by urea breath testing. Outcomes: Eradication charges of group B (lowered amoxicillin-regimen) have been 84.2% in intention-to-treat evaluation and 88.9% in per-protocol evaluation, which have been related with group A (77.8 and 77.8%) and group C (74.6 and 81.0%). Nonetheless, the incidence of hostile occasions in group A was considerably greater than that in group C (22.2 vs. 5.1%, p = 0.027). Conclusions: In H. pylori-positive hemodialysis sufferers, amoxicillin at 250 mg b.i.d. could also be an acceptable scheme for eradication with equal results to the standard remedy and security results for hostile occasions.

© 2018 S. Karger AG, Basel


References

  1. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano Okay, El-Omar EM; European Helicobacter and Microbiota Examine Group and Consensus Panel: Administration of Helicobacter pylori infection-the maastricht V/florence consensus report. Intestine 2017; 66: 6–30.

  2. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami Okay, Satoh Okay, Sugano Okay: Pointers for the administration of Helicobacter pylori an infection in japan: 2009 revised version. Helicobacter 2010; 15: 1–20.

  3. Sugimoto M, Uotani T, Ichikawa H, Andoh A, Furuta T: Gastroesophageal reflux illness in time masking eradication for all sufferers contaminated with Helicobacter pylori in japan. Digestion 2016; 93: 24–31.

  4. Ikizler TA, Cano NJ, Franch H, Fouque D, Himmelfarb J, Kalantar-Zadeh Okay, Kuhlmann MK, Stenvinkel P, TerWee P, Teta D, Wang AY, Wanner C: Prevention and remedy of protein vitality losing in continual kidney illness sufferers: a consensus assertion by the worldwide society of renal diet and metabolism. Kidney Int 2013; 84: 1096–1107.

  5. Kovesdy CP, George SM, Anderson JE, Kalantar-Zadeh Okay: Final result predictability of biomarkers of protein-energy losing and irritation in reasonable and superior continual kidney illness. Am J Clin Nutr 2009; 90: 407–414.

  6. Khedmat H, Ahmadzad-Asl M, Amini M, Lessan-Pezeshki M, Einollahi B, Pourfarziani V, Naseri MH, Davoudi F: Gastro-duodenal lesions and Helicobacter pylori an infection in uremic sufferers and renal transplant recipients. Transplant Proc 2007; 39: 1003–1007.

  7. Sotoudehmanesh R, Ali Asgari A, Ansari R, Nouraie M: Endoscopic findings in end-stage renal illness. Endoscopy 2003; 35: 502–505.

  8. Tsai CJ, Hwang JC: Investigation of higher gastrointestinal hemorrhage in continual renal failure. J Clin Gastroenterol 1996; 22: 2–5.

  9. Chou CC, Bai CH, Tsai SC, Wu MS: Low serum acylated ghrelin ranges are related to the event of heart problems in hemodialysis sufferers. Intern Med 2010; 49: 2057–2064.

  10. Sakao Y, Sugimoto M, Ichikawa H, Sahara S, Tsuji T, Ohashi N, Kato A, Fujigaki Y, Sugimoto Okay, Furuta T, Sakao T, Yasuda H: Severity of gastric mucosal atrophy is the main determinant of plasma ghrelin degree in hemodialysis sufferers. Am J Nephrol 2016; 44: 224–233.

  11. Wynne Okay, Giannitsopoulou Okay, Small CJ, Patterson M, Frost G, Ghatei MA, Brown EA, Bloom SR, Choi P: Subcutaneous ghrelin enhances acute meals consumption in malnourished sufferers who obtain upkeep peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005; 16: 2111–2118.

  12. Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Busbridge M, Brown EA, Taube DH, Ghatei MA, Tam FW, Bloom SR, Choi P: Sustained urge for food enchancment in malnourished dialysis sufferers by day by day ghrelin remedy. Kidney Int 2009; 76: 199–206.

  13. Jang EJ, Park SW, Park JS, Park SJ, Hahm KB, Paik SY, Sin MK, Lee ES, Oh SW, Park CY, Baik HW: The affect of the eradication of Helicobacter pylori on gastric ghrelin, urge for food, and physique mass index in sufferers with peptic ulcer illness. J Gastroenterol Hepatol 2008; 23(suppl 2):S278–S285.

  14. Kawashima J, Ohno S, Sakurada T, Takabayashi H, Kudo M, Ro S, Kato S, Yakabi Okay: Circulating acylated ghrelin degree decreases in accordance with the extent of atrophic gastritis. J Gastroenterol 2009; 44: 1046–1054.

  15. Ichikawa H, Sugimoto M, Sakao Y, Sahara S, Ohashi N, Kato A, Sugimoto Okay, Furuta T, Andoh A, Sakao T, Yasuda H: Relationship between ghrelin, Helicobacter pylori and gastric mucosal atrophy in hemodialysis sufferers. World J Gastroenterol 2016; 22: 10440–10449.

  16. Sugimoto M, Sakai Okay, Kita M, Imanishi J, Yamaoka Y: Prevalence of Helicobacter pylori an infection in long-term hemodialysis sufferers. Kidney Int 2009; 75: 96–103.

  17. Sugimoto M, Uotani T, Sahara S, Ichikawa H, Yamade M, Sugimoto Okay, Furuta T: Efficacy of tailor-made Helicobacter pylori eradication remedy primarily based on clarithromycin susceptibility and upkeep of acid secretion. Helicobacter 2014; 19: 312–318.

  18. Tsujimae M, Yamashita H, Hashimura H, Kano C, Shimoyama Okay, Kanamori A, Matsumoto Okay, Koizumi A, Momose Okay, Eguchi T, Fukuchi T, Fujita M, Okada A: A comparative research of a brand new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of Helicobacter pylori. Digestion 2016; 94: 240–246.

  19. Arancibia A, Drouguett MT, Fuentes G, Gonzalez G, Gonzalez C, Thambo S, Palombo G: Pharmacokinetics of amoxicillin in topics with regular and impaired renal operate. Int J Clin Pharmacol Ther Toxicol 1982; 20: 447–453.

  20. Francke EL, Appel GB, Neu HC: Kinetics of intravenous amoxicillin in sufferers on long-term dialysis. Clin Pharmacol Ther 1979; 26: 31–35.

  21. Adamek RJ, Szymanski C, Pfaffenbach B: Pantoprazole versus omeprazole in one-week low-dose triple remedy for curve of Helicobacter pylori an infection. Am J Gastroenterol 1997; 92: 1949–1950.

  22. Sheu BS, Huang JJ, Yang HB, Huang AH, Wu JJ: The number of triple remedy for Helicobacter pylori eradication in continual renal insufficiency. Aliment Pharmacol Ther 2003; 17: 1283–1290.

  23. Itatsu T, Miwa H, Nagahara A, Kubota M, Miyazaki A, Sato N, Hayashida Y: Eradication of Helicobacter pylori in hemodialysis sufferers. Ren Fail 2007; 29: 97–102.

  24. Chang WC, Jo YI, Park HS, Jegal J, Park JH, Lee JH, Jin CJ: Helicobacter pylori eradication with a 7-day low-dose triple remedy in hemodialysis sufferers. Clin Exp Nephrol 2010; 14: 469–473.

  25. Kobayashi I, Murakami Okay, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma Okay, Nasu M, Fujioka T: Altering antimicrobial susceptibility epidemiology of Helicobacter pylori strains in japan between 2002 and 2005. J Clin Microbiol 2007; 45: 4006–4010.

  26. Sasaki M, Ogasawara N, Utsumi Okay, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai Okay, Joh T: Adjustments in 12-year first-line eradication fee of Helicobacter pylori primarily based on triple remedy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr 2010; 47: 53–58.

  27. Aydemir S, Boyacioglu S, Gur G, Demirbilek M, Can FK, Korkmaz M, Yilmaz U: Helicobacter pylori an infection in hemodialysis sufferers: susceptibility to amoxicillin and clarithromycin. World J Gastroenterol 2005; 11: 842–845.

  28. Klotz U: Pharmacokinetic issues within the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38: 243–270.

  29. Craig WA: Fundamental pharmacodynamics of antibacterials with scientific purposes to the usage of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479–501.

  30. Yamaji Y, Mitsushima T, Ikuma H, Okamoto M, Yoshida H, Kawabe T, Shiratori Y, Saito Okay, Yokouchi Okay, Omata M: Weak response of Helicobacter pylori antibody is excessive threat for gastric most cancers: a cross-sectional research of 10,234 endoscoped Japanese. Scand J Gastroenterol 2002; 37: 148–153.

  31. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, Ishizaki T, Hishida A: Proof that the diploma and length of acid suppression are associated to Helicobacter pylori eradication by triple remedy. Helicobacter 2007; 12: 317–323.


Article / Publication Particulars

First-Web page Preview

Abstract of Original Paper

Obtained: September 14, 2017
Accepted: November 04, 2017
Revealed on-line: January 08, 2018
Subject launch date: February 2018

Variety of Print Pages: 7
Variety of Figures: 4
Variety of Tables: 3

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (On-line)

For added info: https://www.karger.com/DIG


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No a part of this publication could also be translated into different languages, reproduced or utilized in any type or by any means, digital or mechanical, together with photocopying, recording, microcopying, or by any info storage and retrieval system, with out permission in writing from the writer.
Drug Dosage: The authors and the writer have exerted each effort to make sure that drug choice and dosage set forth on this textual content are in accord with present suggestions and observe on the time of publication. Nonetheless, in view of ongoing analysis, modifications in authorities laws, and the fixed move of knowledge referring to drug remedy and drug reactions, the reader is urged to verify the package deal insert for every drug for any modifications in indications and dosage and for added warnings and precautions. That is significantly vital when the advisable agent is a brand new and/or sometimes employed drug.
Disclaimer: The statements, opinions and knowledge contained on this publication are solely these of the person authors and contributors and never of the publishers and the editor(s). The looks of ads or/and product references within the publication isn’t a guaranty, endorsement, or approval of the services or products marketed or of their effectiveness, high quality or security. The writer and the editor(s) disclaim accountability for any harm to individuals or property ensuing from any concepts, strategies, directions or merchandise referred to within the content material or ads.

Leave a Reply

Your email address will not be published. Required fields are marked *